Abstract
The characterization of adnexal masses has been facilitated remarkably by the use of pelvic ultrasound during the last decade. Its ease of use, accessibility, relatively low cost, and the recent introduction of color and duplex scanning has made this modality invaluable. Please see other chapters in this volume for a discussion of the use of ultrasound for differentiating benign from malignant ovarian masses. For patients with advanced ovarian cancer and a known pelvic mass which can be palpated on bimanual exam, however, ultrasonography is rarely helpful other than to confirm the presence of ascites. While magnetic resonance imaging (MRI) provides precise information regarding the location of disease and invasion of tissue planes, such detailed anatomic relationships are generally not clinically relevant for treatment planning in patients with advanced ovarian carcinoma, particularly given the associated costs. This is in contradistinction to cervical cancer, in which MRI has been shown to be sensitive for the detection of parametrial involvement, a parameter which significantly alters the plan of treatment if present (Yu et al. 1998). 18F fluorodeoxyglucose-positron emission tomography (FDG-PET) is highly sensitive for cancerous lesions and may ultimately prove useful for the detection of recurrences, but the cost/benefit ratio is poor for the preoperative evaluation of primary ovarian cancer. Computed tomography (CT) offers advantages over other techniques: relatively low cost, fast scan times, wide availability, and evaluation of the entire abdominal cavity. Furthermore, the use of intravenous and oral contrast improves visualization of retroperitoneal anatomy (Figure 8.1). For these reasons, CT has become a common diagnostic procedure to assess the extent of disease and plan surgical interventions in patients with advanced ovarian cancer. This chapter addresses the use of CT imaging in this cohort of patients and its potential to predict surgical outcome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aletti, G.D., Dowdy, S.C., Gostout, B.S., Jones, M.B., Stanhope, C.R., Wilson, T.O., Podratz, K.C., and Cliby, W.A. (2006) Aggressive surgical effort. and improved survival. in advanced-stage ovarian cancer. Obstet. Gynecol. 107:77–85
Axtell, A.E., Lee, M.H., Bristow, R.E., Dowdy, S.C., Cliby, W.A., Raman, S., Weaver, J.P., Gabbay, M., Ngo, M., Lentz, S., Cass, I., Li, A.J., Karlan, B.Y., and Holschneider, C.H. (2007) Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25:384–389
Bristow, R.E., Duska, L.R., Lambrou, N.C., Fishman, E.K., O’Neill, M.J., Trimble, E.L., and Montz, F.J. (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532–1540
Buist, M.R., Golding, R.P., Burger, C.W., Vermorken, J.B., Kenemans, P., Schutter, E.M., Baak, J.P., Heitbrink, M.A., and Falke, T.H. (1994) Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol. Oncol. 52:191–198
Chi, D.S., Franklin, C.C., Levine, D.A., Akselrod, F., Sabbatini, P., Jarnagin, W.R., DeMatteo, R., Poynor, E.A., Abu-Rustum, N.R., and Barakat, R.R. (2004) Improved optimal cytoreduction rates for stages IIIC. and IV epithelial. ovarian., fallopian tube., and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94:650–654
Choi, H., Choi, S.R., Zhou, R., Kung, H.F., and Chen, I.W. (2004) Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad. Radiol. 11:996–1004
Cooper, B.C., Sood, A.K., Davis, C.S., Ritchie, J.M., Sorosky, J.I., Anderson, B., and Buller, R.E. (2002) Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet. Gynecol. 100:59–64
Dowdy, S.C., Mullany, S.A., Brandt, K.R., Huppert, B.J., and Cliby, W.A. (2004) The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101:346–352
Eisenkop, S.M., Friedman, R.L., and Wang, H.J. (1998) Complete cytoreductive surgery is feasible. and maximizes survival. in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69:103–108
Forstner, R., Hricak, H., Occhipinti, K.A., Powell, C.B., Frankel, S.D., and Stern, J.L. (1995a) Ovarian cancer: staging with CT. and MR imaging. Radiology 197:619–626
Forstner, R., Hricak, H., Powell, C.B., Azizi, L., Frankel, S.B., and Stern, J.L. (1995b) Ovarian cancer recurrence: value of MR imaging. Radiology 196:715–720
Goldie, J.H., and Coldman, A.J. (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer. Treat. Rep. 63:1727–1733
Griffiths, C.T., Parker, L.M., and Fuller, A.F. Jr (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer. Treat. Rep. 63:235–240
Heintz, A.P., Hacker, N.F., Berek, J.S., Rose, T.P., Munoz, A.K., and Lagasse, L.D. (1986) Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet. Gynecol. 67:783–788
HoskinsWJ, McGuire, W.P., Brady, M.F., Homesley, H.D., Creasman, W.T., Berman, M., Ball, H., and Berek, J.S. (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170(4):974–979; discussion 979–980
McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Look, K.Y., Clarke-Pearson, D.L., and Davidson, M. (1996) Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23:40–47
Memarzadeh, S., Lee, S.B., Berek, J.S., Farias-Eisner R (2003) CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer. 13:120–124
Meyer, J.I., Kennedy, A.W., Friedman, R., Ayoub, A., and Zepp, R.C. (1995) Ovarian carcinoma: value of CT in predicting success of debulking surgery. AJR. Am. J. Roentgenol. 165:875–878
Nelson, B.E., Rosenfield, A.T., and Schwartz, P.E. (1993) Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol. 11:166–172
Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Burger, R.A., Mannel, R.S., DeGeest, K., Hartenbach, E.M., and Baergen, R. (2003) Phase III trial of carboplatin. and paclitaxel compared. with cisplatin. and paclitaxel in. patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21:3194–3200
Qayyum, A., Coakley, F.V., Westphalen, A.C., Hricak, H., Okuno, W.T., and Powell, B. (2005) Role of CT. and MR imaging. in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol. Oncol. 96:301–306
Ricke, J., Sehouli, J., Hach, C., Hanninen, E.L., Lichtenegger, W., and Felix, R. (2003) Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur. Radiol. 13:943–949
Santra, S., Liesenfeld, B., Dutta, D., Chatel, D., Batich, C.D., Tan, W., Moudgil, B.M., and Mericle, R.A. (2005) Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J. Nanosci. Nanotechnol. 5:899–904
Schroder, W., Zimny, M., Rudlowski, C., Bull, U., and Rath, W. (1999) The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int. J. Gynecol. Cancer. 9:117–122
Schwartz, P.E., Rutherford, T.J., Chambers, J.T., Kohorn, E.I., and Thiel, R.P. (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol. Oncol. 72:93–99
Semelka, R.C., Lawrence, P.H., Shoenut, J.P., Heywood, M., Kroeker, M.A., and Lotocki, R. (1993) Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre-and postcontrast., fat-suppressed MR imaging., with histologic correlation. J. Magn. Reson. Imaging. 3:99–106
Skipper HE (1978) Adjuvant chemotherapy. Cancer 41:936–940
Stevens, S.K., Hricak, H., and Stern, J.L. (1991) Ovarian lesions: detection and characterization with gadolinium-enhanced MR imaging at 1.5, T. Radiology 181:481–488
van der Burg, M.E., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A.J., Nardi, M., Renard, J., and Pecorelli, S. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research. and Treatment of. Cancer. N. Engl. J. Med. 332:629–634
Yu, K.K., Hricak, H., Subak, L.L., Zaloudek, C.J., and Powell, C.B. (1998) Preoperative staging of cervical carcinoma: phased array coil fast spin-echo versus body coil spin-echo T2-weighted MR imaging. AJR. Am. J. Roentgenol. 171:707–711
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Dowdy, S.C., Cliby, W.A. (2010). Advanced Ovarian Cancer: Prediction of Surgical Outcomes Using Computed Tomography. In: Hayat, M. (eds) Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2918-8_8
Download citation
DOI: https://doi.org/10.1007/978-90-481-2918-8_8
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2917-1
Online ISBN: 978-90-481-2918-8
eBook Packages: MedicineMedicine (R0)